US3764699A - Methods for relieving bronchial spasm with prostaglandin-f{11 and derivatives - Google Patents

Methods for relieving bronchial spasm with prostaglandin-f{11 and derivatives Download PDF

Info

Publication number
US3764699A
US3764699A US00204304A US3764699DA US3764699A US 3764699 A US3764699 A US 3764699A US 00204304 A US00204304 A US 00204304A US 3764699D A US3764699D A US 3764699DA US 3764699 A US3764699 A US 3764699A
Authority
US
United States
Prior art keywords
prostaglandin
methods
bronchial spasm
oral
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00204304A
Other languages
English (en)
Inventor
M Rosenthale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of US3764699A publication Critical patent/US3764699A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Definitions

  • ABSTRACT Prostaglandin-F 7-[3a,5B-dihydroxy-2-(3-hydroxyl-octenyl)cyclopentyl]-5-hepten0ic acid, its esters, alkali metal salts, and amine salts provide potent and nont ox i c .comgosjtiqns and methods for relieving bronchial spasm and facilitating breathing in warm-blooded animals. Administration by the oral inhalation route is particularly efficacious.
  • bronchodilators i.e., substances able to relax and smooth muscle of the bronchial tree and thus control spasm and facilitate breathing in conditions affecting animals, such as bronchial asthma, bronchitis, bronchietasis, pneumonia, emphysema, and the like.
  • bronchodilator preparations incorporate one or more of three basic types of compounds: (a) sympathomimetic (adrenergic) agents, (b) xanthine derivatives and (c) corticosteroids. These agents are frequently used in combination with anti-tussives, expectorants, mucolytics, and the like.
  • the sympathomimetic agents most often used are epinephrine, isoproterenol, phenylephrine and ephedrine. These adrenergic agents are most powerful and useful drugs in the relief of severe asthmatic spasm (status asthmaticus); however, as with other dilators they have untoward side effects. Some of the more undesirable of these are stimulation of the cardiovascular and central nervous system, hyperglycemic and tolerance (tachyphylaxis), which greatly reduces the effectiveness of these drugs.
  • the two xanthine derivatives most widely used are theophylline and aminophylline.
  • Some of the problems associated with therapy with these drugs include variable oral absorption, cardiovascular effects and inability to achieve adequate levels without gastric irritation.
  • the agents presently available to the physician have a number of problems associated with their use, including toxicity, low activity (especially in the Xanthines), adverse effect on the cardiovascular system (especially in the sympathomimetics) and fluid retention or edema (with the corticosteroids).
  • bronchoconstricting agent is art recognized as such, as, for example, in Sweatman et al., Nature, 217, 69 (1968);
  • prostaglandin-F 3 which possesses the identical side-chain unsaturation as the bronchoconstricting compound PGF, and which lacks the Sa-hydroxy configuration of PGF, a and PGE, is itself a potent bronchodilating agent which provides methods and compositions for producing bronchodilation and reducing bronchial spasm in warm-blooded animals.
  • the invention sought to be patented in its process aspect resides in the concept of a method of relieving bronchial spasm and facilitating breathing in warmblooded animals which comprises administering to a warm-blooded animal in need thereof an amount sufficient to relieve bronchial spasm and facilitate breathing in said warm-blooded animal of a'composition comprising: (a) a compound of the formula OH OH wherein R is hydrogen, alkyl of from one up to about six carbon atoms, alkali metal, or a pharmacologically acceptable cation derived from ammonia or a basic amine; and (b) a pharmacologically acceptable inhalation carrier, in an amount sufficient to provide a composition administerable by the oral inhalation route.
  • the esters of formula I are prepared by standard methods, such as'for example, by treating a solution of the free acids with diazomethane or other appropriate diazohydrocarbons, such as diazoethane, l-diazo-Z-ethylpentane, and the like.
  • the alkali metal carboxylates of the invention can be prepared by mixing stoichiometrically equivalent amounts of the free acids of formula I, preferably in aqueous solution, with solutions of alkali metal bases, such as sodium, potassium, and lithium hydroxides or carbonates, and the like, then freeze drying the mixture to leave the product as a residue.
  • the amine salts are prepared by mixing the free acids, preferably in solution, with a solution of the appropriate amine, in water, isopropanol, or the like, and freeze drying the mixture to leave the product as a residue.
  • alkyl of from about one to about six carbon atoms when used herein and in the appended claims includes straight and branched chain hydrocarbon radicals, illustrative members of which are methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, nhexyl, 3-methylpentyl, 2,3-dimethylbutyl, and the like.
  • Alkali metal includes, for example, sodium, potassium, lithium, and the like.
  • a pharmacologically acceptable cation derived from ammonia or a basic amine contemplates the positively charged ammonium ion and analogous ions derived from organic nitrogenous bases strong enough to form such cations.
  • Bases useful for the purpose of forming pharmacologically acceptable non-toxic addition salts of such compounds containing free carboxyl groups form a class whose limits are readily understood by those skilled in the art. Merely for illustration, they can be said to comprise, in cationic form, those of the formula:
  • R, R and R independently, are hydrogen, alkyl of from about one to about six carbon atoms, cycloalkyl of from about three to about six carbon atoms, monocarbocyclicaryl of about six carbon atoms, monocarbocyclicarylalkyl of from about seven to about ll carbon atoms, hydroxyalkyl of from about one to about three carbon atoms, or monocarbocyclicarylhydroxyalkyl of from about seven to about 15 carbon atoms or, when taken together with the nitrogen atom to which they are attached, any two of R, R and R form part of a 5 to 6-membered heterocyclic ring containing carbon, hydrogen, oxygen, or nitrogen, said heterocyclic rings and said monocarbocyclicaryl groups being unsubstituted or monoor dialkyl substituted, said alkyl groups containing from about one to about six carbon atoms.
  • R groups comprising pharmacologically-acceptable cations derived from ammonia or a basic amine are ammonium, mono-, di-, and tri-methylammonium, mono-, diand triethylammonium, mono-, di-, and tripropylammonium (iso and normal), ethyldimethylammonium, benzyldimethylammonium cyclohexylammonium benzylammonium, dibenzylammonium, piperidinium, morpholinium, pyrrolidinium, piperazinium, 1- methylpiperidinium, 4-ethylmorpholinium l-isopropylpyrrolidinium, l,4-dimethylpiperazinium, l-nbutylpiperidinium, Z-methylpiperidinium, l-ethyl-Z- methylpiperidinium, mono-, diand triethanolammonium, ethyldiethanol
  • the instant compositions can be administered in a variety of dosage forms, the oral route being used primarily for maintenance therapy while injectables tend to be more useful in acute emergency situations. Inhalation (aerosols and solution for nebulizers) seems to be somewhat faster acting than other oral forms but slower than injectables and this method combines the advantages of maintenance and moderately-acute stage therapy in one dosage unit.
  • the daily dose requirements vary with the particular compositions being employed, the severity of the symptoms being presented, and the animal being treated.
  • the dosage varies with the size of the animal.
  • the oral inhalation route with for example a hand nebulizer or a pressurized aerosol dispenser the dose is from about 5 micrograms to about 100 micrograms, and preferably from about to about 50 micrograms, approximately every 4 hours, or as needed.
  • the effective dose is from about 1 to about 20 mg., preferably from about 5 to about 10 mg. up to a total of about 40 mg. per day.
  • the ordinarily effective dose is from about 50 micrograms to about 300 micrograms, preferably about 200 micrograms per day.
  • the active ingredient can be compounded into any of the usual oral dosage forms including tablets, capsules and liquid preparations such as elixirs and suspensions containing various coloring, flavoring, stabilizing and flavor masking substances.
  • oral dosage forms the active ingredient can be diluted with various tableting materials such as starches of various types, calcium carbonate, lactose, sucrose and dicalcium phosphate to simplify the tableting and capsulating process.
  • a minor proportion of magnesium stearate is useful as a lubricant.
  • the proportion of the active ingredient in said composition will be sufficient to impart bronchodilating activity thereto. This will range upward from about 0.0001 percent by weight of active ingredient in said composition.
  • the instant active ingredient in dilute aqueous solution, preferably at concentrations of 9 about 1 part of medicament to from about 100 to 200 parts by weight of total solution.
  • Entirely conventional additives may be employed to stabilize these solutions or to provide isotonic media, for example, sodium chloride, sodium citrate, citric acid, sodium bisulfite, and the like can be employed.
  • the composition can comprise the active ingredient suspended in an inert propellant (such as a mixture of dichlorodifluoromethane and dichlorotetrafluoroethane) together with a co-solvent, such as ethanol, flavoring materials and stabilizers.
  • a co-solvent such as ethanol, flavoring materials and stabilizers.
  • a dispersing agent such as oleyl alcohol.
  • EXAMPLE 1 Anesthetized (Dial-urethane) guinea pigs were artificially respired at a constant positive air pressure (Starling miniature pump) and changes in tidal air during inspiration were recorded, according to the method of Rosenthale et al., Int. Arch. Pharmacol., 172, 91 (1968).
  • the bronchoconstrictor agent acetylcholine was administered at doses of 10 to 40 meg/kg depending on each animal's sensitivity to this compound, and control responses to acetylcholine were thus established. Bronchoconstrictor agents raise the resistance of the lungs to inflation thereby decreasing the tidal air flow.
  • Prostaglandin-F B was then administered either intravenously or by aerosol, and the animals were then challenged again with acetylcholine, and the degree of inhibition of bronchoconstriction by PGF2 B was thus determined.
  • EXAMPLE 2 A composition is prepared comprising 1 part of 7- [3a,5B-dihydroxy-2-( 3-hydroxyl -octenyl)cyclopentyl]-5-heptenoic acid and 300 parts by weight of 0.06 M aqueous phosphate buffer.
  • a hand nebulizer for administration to relieve bronchial spasm by oral inhalation with a hand nebulizer, in animals of from about 20 to about 80 kilograms body weight, three to five inhalations of the solution are used every 4 hours.
  • EXAMPLE 3 Tablets for oral use are prepared with the following formulations:
  • Magnesium stearate 3 3 300 300 One tablet containing either 5 or l0 mg. of active ingredient is administered to an animal of about kg. body weight suffering from bronchial spasm. Up to a total of about 40 mg. per day can be well tolerated in divided doses.
  • a suitable measured quantity of the medicament is mixed with, and dissolved in, a measured amount of the cosolvent.
  • a stabilizer, if desired, is added.
  • a measured quantity of the resulting solution is then introduced into an open container.
  • the open container and its contents are then cooled, preferably to a temperature below the boiling point of the propellant to be employed. A temperature of 25F. is usually satisfactory.
  • a measured quantity of the liquified propellant which also has been cooled below its boiling point is then introduced into the container and mixed with the solution already present.
  • the quantities of the components introduced into the container are calculated to provide the desired concentration in each of the final compositions.
  • the container is sealed with a closure equipped with a suitable dispensing valve arrangement. Upon warming to room temperature the contents of the container are mixed by agitation of the container to insure complete solution of the medicament. The sealed container is then ready to dispense the composition and provide the medicament in aerosol form.”
  • Nebulizing units each containing 15 ml. are filled according to the manipulative procedure described above with the following composition:
  • An injectable unit dosage composition is prepared by dissolving 100 mg. of 7-[3a,5;3-dihydroxy-2-(3- hydroxyl-octenyl)cyclopentyl]-5-heptanoic acid in 30 ml. of 0.2 M sodium phosphate buffer, pH 7.4 and is made up to 100 ml. with distilled water.
  • This solution of medicament, containing 1 rng./ml. of active ingredient (calculated as the free acid) is stored frozen at C. until thawed for sterile filtration. After sterile filtration through a 0.45 micron filter, 1 ml. aliquots are filled aseptically into sterile ampules. The ampules are flame sealed and the contents are frozen and stored at 20C. until needed.
  • a method of relieving bronchial spasm and facilitating breathing in warm-blooded animals which comprises administering to a warm-blooded animal in need thereof an amount sufficient to relieve bronchial spasm and facilitate breathing in said warm-blooded animal of a composition comprising:
  • R is hydrogen, alkyl of from one up to about six carbon atoms, alkali metal, or a pharmacologically acceptable cation derived from ammonia or a basic amine;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US00204304A 1971-12-02 1971-12-02 Methods for relieving bronchial spasm with prostaglandin-f{11 and derivatives Expired - Lifetime US3764699A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20430471A 1971-12-02 1971-12-02

Publications (1)

Publication Number Publication Date
US3764699A true US3764699A (en) 1973-10-09

Family

ID=22757373

Family Applications (1)

Application Number Title Priority Date Filing Date
US00204304A Expired - Lifetime US3764699A (en) 1971-12-02 1971-12-02 Methods for relieving bronchial spasm with prostaglandin-f{11 and derivatives

Country Status (8)

Country Link
US (1) US3764699A (cs)
AU (1) AU4946172A (cs)
BE (1) BE792216A (cs)
DE (1) DE2257464A1 (cs)
FR (1) FR2162192B1 (cs)
GB (1) GB1401490A (cs)
NL (1) NL7216378A (cs)
ZA (1) ZA728016B (cs)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154407A1 (en) * 2005-12-01 2007-07-05 Boehringer Ingelheim International Gmbh Inhaler and store for a dry medicament formulation and related methods and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pickles Biological Reviews Vol. 42, (1967), pages 627 629. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154407A1 (en) * 2005-12-01 2007-07-05 Boehringer Ingelheim International Gmbh Inhaler and store for a dry medicament formulation and related methods and use thereof

Also Published As

Publication number Publication date
FR2162192A1 (cs) 1973-07-13
AU4946172A (en) 1974-05-30
DE2257464A1 (de) 1973-06-07
ZA728016B (en) 1973-07-25
NL7216378A (cs) 1973-06-05
GB1401490A (en) 1975-07-16
FR2162192B1 (cs) 1976-12-03
BE792216A (fr) 1973-06-01

Similar Documents

Publication Publication Date Title
EP1045695B1 (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease
US3987192A (en) Compositions and process of treatment
US3922340A (en) Pharmaceutical compositions for treating lung diseases
US3764699A (en) Methods for relieving bronchial spasm with prostaglandin-f{11 and derivatives
US3755599A (en) Methods for relieving bronchospasm with prostaglandin a compounds
EP0552205B1 (en) New medical use for a certain indole derivative and pharmaceutical composition containing it
US4385048A (en) Methods for the treatment of nasal hypersecretion
US3755426A (en) 10-haloprostaglandin-a derivatives
US3644638A (en) Compositions and methods for relieving bronchial spasm with prostanoic acids and esters
US4091015A (en) 15-Substituted prostanoic acids
IE59327B1 (en) Prazosin-pirbuterol combination for bronchodilation
US4016279A (en) Spray compositions for inhalation therapy of bronchial disorders
US3504020A (en) Prostaglandin thiosemicarbazones,1-ester and 1-carbinol derivatives thereof
US3836667A (en) Method of producing bronchodilation
US3972917A (en) 11-Deoxy 15-methyl prostaglandin E1
US4097596A (en) Inhalation therapy for relieving bronchial spasm using quaternary salts of promethazine
US3501525A (en) Prostaglandin ureides
CA2264172A1 (en) Remedies for allergic dermatitis
US4001314A (en) 15-Ethynyl-PGE2
JPH0213644B2 (cs)
US4011338A (en) 15-methyl prostaglandin compounds having bronchodilating activity
GB1560463A (en) Heparin - based medicament adminstrable by the tracheo-bronchial and alveolar route
Ono et al. Interaction between aspirin and prostaglandins in the isolated guinea-pig tracheal muscle
US4022912A (en) Use of 1-decarboxy-1-hydroxymethyl-PGE1 in therapeutic bronchodilation
US4243679A (en) S-(3-Methyl-2-butenyl)cysteine